NEWSROOM Press Releases

    Year
    2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

    254 Results

    New Data from Phase III Lung Cancer Trial Show VeriStrat® Identifies Patients Likely to Respond to Erlotinib

    May 6, 2010

    Phase III trial shows that VeriStrat identified patients likely to respond to erlotinib (Tarceva.)

    VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    April 19, 2010

    Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.

    Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    June 21, 2010

    Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.

    Biodesix CEO to Present at Personalized Medicine Partnerships Conference

    February 5, 2010

    Biodesix's CEO, David Brunel, will present at the 2010 Personalized Medicine Partnerships conference, Wednesday, February 24th, at 11:00 a.m. eastern time.

    VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

    November 19, 2010

    The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.

    Biodesix Selected as a Colorado Company to Watch

    June 23, 2010

    Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.

    Biodesix Completes Series C Financing and Receives Grant

    November 5, 2010

    Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.